参考文献
1
中华医学会骨质疏松和骨矿盐疾病分会.
中国骨质疏松症流行病学调查及"健康骨骼"专项行动结果发布[J].
中华骨质疏松和骨矿盐疾病杂志,
2019,
12(
4):
317-
318.
.
2
谢雅, 杨克虎, 吕青, 等.
强直性脊柱炎/脊柱关节炎患者实践指南[J].
中华内科杂志,
2020,
59(
7):
511-
518.
.
3
中华医学会骨质疏松和骨矿盐疾病分会.
原发性骨质疏松症诊疗指南(2017)[J].
中华骨质疏松和骨矿盐疾病杂志,
2017,
10(
5):
413-
443.
.
4
KataokaY, LuoY, ChaimaniA, et al.
Cumulative network meta-analyses, practice guidelines, and actual prescriptions for postmenopausal osteoporosis: a meta-epidemiological study[J].
Arch Osteoporos,
2020,
15(
1):
21.
.
5
ClynesMA, HarveyNC, CurtisEM, et al.
The epidemiology of osteoporosis[J].
Br Med Bull,
2020,
133(
1):
105-
117.
.
6
DrakeMT, MuradMH, MauckKF, et al.
Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis[J].
J Clin Endocrinol Metab,
2012,
97(
6):
1861-
1870.
.
7
De LaetC, KanisJA, OdenA, et al.
Body mass index as a predictor of fracture risk: a meta-analysis[J].
OsteoporosInt,
2005,
16(
11):
1330-
1338.
.
8
KazeAD, RosenHN, PaikJM.
A meta-analysis of the association between body mass index and risk of vertebral fracture[J].
Osteoporos Int,
2018,
29(
1):
31-
39.
.
9
XiangBY, HuangW, ZhouGQ, et al.
Body mass index and the risk of low bone mass-related fractures in women compared with men: a PRISMA-compliant meta-analysis of prospective cohort studies[J].
Medicine,
2017,
96(
12):
e5290.
.
10
MazoccoL, ChagasP.
Association between body mass index and osteoporosis in women from northwestern RioGrande do Sul[J].
Rev Bras Reumatol Engl Ed,
2017,
57(
4):
299-
305.
.
11
WuZJ, ZhaoP, LiuB, et al.
Effect of cigarette smoking on risk of hip Fracture in men: a meta-analysis of 14 prospective cohort studies[J].
PLoS One,
2016,
11(
12):
e0168990.
.
12
ShenGS, LiY, ZhaoG, et al.
Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies[J].
Injury,
2015,
46(
7):
1333-
1340.
.
13
KanisJA, JohnellO, OdenA, et al.
Smoking and fracture risk: a meta-analysis[J].
OsteoporosInt,
2005,
216:
155-
162.
.
14
BijelicR, MilicevicS, BalabanJ.
Risk factors for osteoporosis in postmenopausal women[J].
Med Arch,
2017,
71(
1):
25-
28.
.
15
CheraghiZ, Doosti-IraniA, Almasi-HashianiA, et al.
The effect of alcohol on osteoporosis: a systematic review and meta-analysis[J].
Drug Alcohol Dependence,
2019,
197:
197-
202.
.
16
中国营养学会.
中国居民膳食指南(2016)[M].
北京:
人民卫生出版社,
2016.
17
GallacherSJ, GallagherAP, McQuillianC, et al.
The prevalence of vertebral fracture amongst patients presenting with non-vertebral fractures[J].
OsteoporosInt,
2007,
18(
2):
185-
192.
.
18
中华医学会骨质疏松和骨矿盐疾病分会.
骨质疏松性椎体压缩性骨折诊疗与管理专家共识[J].
中华骨质疏松和骨矿盐疾病杂志,
2018,
11(
5):
425-
437.
.
19
CompstonJ, CooperA, CooperC, et al.
UK clinical guideline for the prevention and treatment of osteoporosis[J].
Arch Osteoporos,
2017,
12(
1):
43.
.
20
KanisJA, GlüerCC.
An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of scientific advisors, International Osteoporosis Foundation[J].
Osteoporos Int,
2000,
11(
3):
192-
202.
.
21
KanisJA, McCloskeyEV, JohanssonH, et al.
A reference standard for the description of osteoporosis[J].
Bone,
2008,
42(
3):
467-
475.
.
22
CosmanF, de BeurSJ, LeBoffMS, et al.
Clinician′s guide to prevention and treatment of osteoporosis[J].
Osteoporos Int,
2014,
25(
10):
2359-
2381.
.
23
CurtisJ, WestfallAO, AllisonJ, et al.
Population-based assessment of adverse events associated with long-term glucocorticoid use[J].
Arthritis Rheum,
2006,
55(
3):
420-
426.
.
24
AngeliA, GuglielmiG, DovioA, et al.
High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study[J].
Bone,
2006,
39(
2):
253-
259.
.
25
LeBlancCM, MaJ, TaljaardM, et al.
Incident vertebral fractures and risk factors in the first three years following glucocorticoid initiation among pediatric patients with rheumatic disorders[J].
J Bone Miner Res,
2015,
30(
9):
1667-
1675.
.
26
BuckleyL, GuyattG, FinkHA, et al.
2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis[J].
Arthritis Rheumatol,
2017,
69(
8):
1521-
1537.
.
27
中华医学会风湿病学分会.
糖皮质激素诱导的骨质疏松诊治的专家共识[J].
中华风湿病学杂志,
2013,
17(
6):
363-
368.
.
28
ArdenNK, BakerJ, HoggC, et al.
The heritability of bone mineral density, ultrasound of the calcaneus and hip axis length: a study of postmenopausal twins[J].
J Bone Miner Res,
1996,
11(
4):
530-
534.
.
29
NgMY, ShamPC, PatersonAD, et al.
Effect of environmental factors and gender on the heritability of bone mineral density and bone size[J].
Ann Hum Genet,
2006,
70(Pt
4):
428-
438.
.
30
IoannidisJP, NgMY, ShamPC, et al.
Meta-analysis of genome-wide scans provides evidence for sex-and site-specific regulation of bone mass[J].
J Bone Miner Res,
2007,
22(
2):
173-
183.
.
31
EstradaK, StyrkarsdottirU, EvangelouE, et al.
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture[J].
Nat Genet,
2012,
44(
5):
491-
501.
.
32
GiampietroPF, McCartyC, MukeshB, et al.
The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the marshfield clinic personalized medicine cohort[J].
Osteoporos Int,
2010,
21(
3):
467-
477.
.
33
OfluogluO,OfluogluD.
A case report: pregnancy-in-duced severe osteoporosis with-eight vertebral fractures[J].
Rheumatol Int,
2008,
29(
2):
197-
201.
.
34
OzturkC, AtamazFC, AkkurtH, et al.
Pregnancy-asso-ciated osteoporosis presenting severe vertebral fractures[J].
J Obstet Gynaecol Res,
2014,
40(
1):
288-
292.
.
35
KarlssonMK, AhlborgHG, KarlssonC.
Maternity and bone mineral density[J].
Acta Orthop,
2005,
76(
1):
2-
13.
.
36
Holmberg-MarttilaD, LeinoA, SievänenH.
Bone turnover markers during lactation, postpartum amenorrhea and resumption of menses[J].
Osteoporos Int,
2003,
14(
2):
103-
109.
.
37
WysolmerskiJJ.
Interactions between breast, bone, and brain regulate mineral and skeletal metabolism during lactation[J].
Ann N Y Acad Sci,
2010,
1192:
161-
169.
.
38
SowersM, EyreD, HollisBW, et al.
Biochemical markers of bone turnover in lactating and nonlactating postpartum women[J].
J Clin Endocrinol Metab,
1995,
80(
7):
2210-
2216.
.
39
SowersMF,HollisBW,ShapiroB,et al.
Elevated parathyroid hormone-related peptide associated with lactation and bone density loss[J].
JAMA,
1996,
276(
7):
549-
554.
.
40
ViswanathanM, ReddyS, BerkmanN,et al.
Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US preventive services task force[J].
JAMA,
2018,
319 (
24):
2532-
2551.
.
41
CummingsSR, San MartinJ, McClungMR, et al.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J].
N Engl J Med,
2009,
361(
8):
756-
765.
.
42
NeerRM, ArnaudCD, ZanchettaJR, et al.
Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis[J].
N Engl J Med,
2001,
344(
19):
1434-
1441.
.
43
EttingerB, BlackDM, MitlakBH, et al.
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifeneevaluation(MORE) investigators[J].
JAMA,
1999,
282(
7):
637-
645.
.
44
3rd ChesnutCH, SilvermanS, AndrianoK, et al.
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group[J].
Am J Med,
2000,
109(
4):
267-
276.
.
45
BlackDM, SchwartzAV, EnsrudKE, et al.
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension(FLEX): a randomized trial[J].
JAMA,
2006,
296(
24):
2927-
2938.
.
46
BlackDM, DelmasPD, EastellR, et al.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis[J].
N Engl J Med,
2007,
356(
18):
1809-
1822.
.
47
Dawson-HughesB, TostesonAN, 3rdMelton LJ, et al.
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA[J].
OsteoporosInt,
2008,
19(
4):
449-
458.
.
48
CummingsSR, BlackDM, ThompsonDE, et al.
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial[J].
JAMA,
1998,
280(
24):
2077-
2082.
.
49
BonaiutiD, SheaB, IovineR, et al.
Exercise for preventing and treating osteoporosis in postmenopausal women[J].
Cochrane Database Syst Rev,
2002, (
3):
CD000333.
.
50
FrancoMR, PereiraLS, FerreiraPH.
Exercise interventions for preventing falls in older people living in the community[J].
Br J Sports Med,
2014,
48(
10):
867-
868.
.
51
El-KhouryF, CassouB, CharlesMA, et al.
The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials[J].
BMJ,
2013,
347:
f6234.
.
52
TaiV, LeungW, GreyA, et al.
Calcium intake and bone mineral density: systematic review and meta-analysis[J].
BMJ,
2015,
351:
h4183.
.
53
BollandMJ, LeungW, TaiV, et al.
Calcium intake and risk of fracture: systematic review[J].
BMJ,
2015,
351:
h4580.
.
54
中国营养学会.
中国居民膳食营养素参考摄入量速查手册[M].
北京:
中国标准出版社,
2014.
55
LuH,ZhangZ,KeY,et al.
High prevalence of vitamin D insufficiency in China: relationship with the levels of parathyroid hormone and markers of bone turnover[J].
PLoS One,
2012,
7:
e47264.
.
56
NingZ,SongS,MiaoL,et al.
High prevalence of vitamin D deficiency in urban health checkup population[J].
Clin Nutr,
2016,
35(
4):
859-
863.
.
57
ZhaoJ,XiaW,NieM,et al.
The levels of bone turnover markers in Chinese postmenopausal women: peking vertebral fracture study[J].
Menopause,
2011,
18(
11):
1237-
1243.
.
58
Bischoff-FerrariHA,Dawson-HughesB,StaehelinHB,et al.
Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials[J].
BMJ,
2009,
339:
b3692.
.
59
RussellRG,WattsNB,EbetinoFH,et al.
Mechanisms of action of bisphosphonates: similarities and differencesand their potential influence on clinical efficacy[J].
OsteoporosInt,
2008,
19(
6):
733-
759.
.
60
RussellRG.
Bisphosphonates: the first 40 years[J].
Bone,
2011,
49(
1):
2-
19.
.
61
BoneHG,HoskingD,DevogelaerJP,et al.
Ten years′ experience with alendronate for osteoporosis in postmenopausal women[J].
N Engl J Med,
2004,
350(
12):
1189-
1199.
.
62
LylesKW,Colon-EmericCS,MagazinerJS,et al.
Zoledronic acid and clinical fractures and mortality after hip fracture [J].
N Engl J Med,
2007,
357(
18):
1799-
1809.
.
63
McclungMR,GeusensP,MillerPD,et al.
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group[J].
N Engl J Med,
2001,
344(
5):
333-
340.
.
64
ChesnutCH,SkagA,ChristiansenC,et al.
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis[J].
J Bone Miner Res,
2004,
19(
8):
1241-
1249.
.
65
HarrisST, WattsNB, JacksonRD, et al.
Four-year study of intermittent cyclic etidronate treatment of post-menopausal osteoporosis: three years of blinded therapy followed by one year of open therapy[J].
Am J Med,
1993,
95(
6):
557-
567.
.
66
GuJM,WangL,LinH,et al.
The efficacy and safety of weekly 35-mg risedronate dosing regimen for Chinese postmenopausal women with osteoporosis or osteopenia: 1-year data [J].
Acta Pharmacol Sin,
2015,
36(
7):
841-
846.
.
67
ZhangZL,LiaoEY,XiaWB,et al.
Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month,randomized,open-label,active-comparator-controlled study with a 6-month extension[J].
Osteoporos Int,
2015,
26(
9):
2365-
2374.
.
68
JensenAL, LomborgK, WindG, et al.
Effectiveness and characteristics of multifaceted osteoporosis group education--asystematic review[J].
Osteoporos Int,
2014,
25(
4):
1209-
1224.
.
69
KalkımAslı, DağhanŞafak.
Theory-based osteoporosis prevention education and counseling program for women: arandomized controlled trial[J].
Asian Nurs Res,
2017,
11(
2):
119-
127.
.
70
WangL, XuX, ZhangY, et al.
A model of health education and management for osteoporosis prevention[J].
Exp Ther Med,
2016,
12(
6):
3797-
3805.
.